Asio Capital LLC increased its position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 2.4% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,689 shares of the company’s stock after purchasing an additional 229 shares during the quarter. Asio Capital LLC’s holdings in Elevance Health were worth $5,038,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of ELV. Bank & Trust Co purchased a new stake in shares of Elevance Health in the second quarter valued at approximately $27,000. Opal Wealth Advisors LLC purchased a new stake in shares of Elevance Health during the second quarter worth approximately $28,000. Palisade Asset Management LLC purchased a new stake in shares of Elevance Health during the first quarter worth approximately $28,000. Register Financial Advisors LLC purchased a new stake in shares of Elevance Health during the first quarter worth approximately $32,000. Finally, Beaird Harris Wealth Management LLC purchased a new stake in shares of Elevance Health during the fourth quarter worth approximately $32,000. 89.24% of the stock is owned by institutional investors and hedge funds.
Elevance Health Trading Up 2.0 %
NYSE:ELV opened at $501.88 on Friday. The firm has a market cap of $116.38 billion, a P/E ratio of 17.60, a PEG ratio of 1.08 and a beta of 0.82. The company has a current ratio of 1.49, a quick ratio of 1.49 and a debt-to-equity ratio of 0.58. The stock’s 50 day simple moving average is $531.94 and its 200-day simple moving average is $529.01. Elevance Health, Inc. has a 12-month low of $435.99 and a 12-month high of $567.26.
Elevance Health Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 25th. Investors of record on Tuesday, September 10th were given a dividend of $1.63 per share. The ex-dividend date was Tuesday, September 10th. This represents a $6.52 annualized dividend and a yield of 1.30%. Elevance Health’s dividend payout ratio (DPR) is presently 22.86%.
Insider Buying and Selling
In other Elevance Health news, Director Ramiro G. Peru sold 753 shares of the company’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $531.52, for a total transaction of $400,234.56. Following the completion of the sale, the director now directly owns 8,744 shares in the company, valued at $4,647,610.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CEO Gail Boudreaux sold 34,000 shares of the stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $500.98, for a total value of $17,033,320.00. Following the completion of the sale, the chief executive officer now owns 126,709 shares in the company, valued at approximately $63,478,674.82. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ramiro G. Peru sold 753 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $531.52, for a total value of $400,234.56. Following the completion of the sale, the director now owns 8,744 shares of the company’s stock, valued at approximately $4,647,610.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,058 shares of company stock worth $17,588,116. 0.35% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Several analysts have issued reports on ELV shares. Cantor Fitzgerald restated an “overweight” rating and issued a $600.00 target price on shares of Elevance Health in a report on Tuesday, October 1st. Wells Fargo & Company decreased their price target on Elevance Health from $600.00 to $593.00 and set an “overweight” rating on the stock in a research note on Monday, July 22nd. TD Cowen decreased their price target on Elevance Health from $624.00 to $589.00 and set a “buy” rating on the stock in a research note on Friday, July 19th. Stephens reaffirmed an “overweight” rating and issued a $615.00 price target on shares of Elevance Health in a research note on Thursday, September 5th. Finally, Truist Financial upped their price target on Elevance Health from $600.00 to $620.00 and gave the stock a “buy” rating in a report on Monday, July 15th. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $605.07.
Get Our Latest Stock Report on ELV
Elevance Health Profile
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Featured Stories
- Five stocks we like better than Elevance Health
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- How to Calculate Retirement Income: MarketBeat’s Calculator
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Differences Between Momentum Investing and Long Term Investing
- MarketBeat Week in Review – 10/7 – 10/11
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.